FDAapproval84% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Amgen; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · NRG1 Fusion-Positive Cholangiocarcinoma
- Sub-indication
- General
Related signal: FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma